American Society of Hematology

Fig. 5.

$Fig. 5. Cotreatment with Smac-4 peptide enhances Epo B– or Apo-2L/TRAIL–induced apoptosis of Jurkat cells. / Jurkat cells were treated with either 10 μM of control or Smac-4 peptide for 3 hours, followed by treatment with 10 nM Epo B or 2.5 ng/mL Apo-2L/TRAIL and/or the control or Smac-4 peptide for 24 hours. Following these treatments, the percentage of apoptotic cells (hypodiploid and sub-G1 fraction) was determined by propidium iodide staining followed by flow cytometry. Values represent the mean ± SE of 3 experiments.$

Cotreatment with Smac-4 peptide enhances Epo B– or Apo-2L/TRAIL–induced apoptosis of Jurkat cells.

Jurkat cells were treated with either 10 μM of control or Smac-4 peptide for 3 hours, followed by treatment with 10 nM Epo B or 2.5 ng/mL Apo-2L/TRAIL and/or the control or Smac-4 peptide for 24 hours. Following these treatments, the percentage of apoptotic cells (hypodiploid and sub-G1 fraction) was determined by propidium iodide staining followed by flow cytometry. Values represent the mean ± SE of 3 experiments.

This Feature Is Available To Subscribers Only